Rimini Street Expands APAC Investment to South Korea and Appoints IT Industry Veteran to Lead New Operations
Rimini Street, Inc., the leading global independent provider of enterprise software support services for SAP SE’s (NYSE:SAP) Business Suite, BusinessObjects and HANA Database software and Oracle Corporation’s (NYSE:ORCL) Siebel, PeopleSoft, JD Edwards, E-Business Suite, Oracle Database, Oracle Middleware, Hyperion, Oracle Retail and Oracle Agile PLM software, today announced its expanded investment and presence in the APAC region with the launch of its local operations in South Korea. Rimini Street also announced the appointment of Sangyoul Kim as country manager, South Korea. In this newly created role, Mr. Kim is responsible for leading the growth and development in the region, which represents the twelfth largest economy in the world and a large market opportunity for the Company. Rimini Street’s expansion to South Korea is driven by strong local demand for its award-winning, premium enterprise software support that delivers a comprehensive, hyper-responsive, support alternative as compared to expensive Oracle and SAP vendor maintenance. Rimini Street’s investment in South Korea builds on the Company’s accelerating growth trajectory in the APAC region that includes a 90% increase in APAC revenue for the 12-month period ending June 30, 2016, compared with the prior 12-month period. Rimini Street’s support is available immediately for South Korean companies.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160816006207/en/
Sangyoul Kim, country manager for Rimini Street South Korea (Photo: Business Wire)
Strong Demand Drives Rimini Street Expansion into South Korea
South Korea is one of the most highly developed information and communications technology markets in the world and has been part of the Company’s planned growth strategy in the APAC region. The region is rapidly growing for Rimini Street, with a 117% increase in total signed clients to date for the 12-month period ending June 30, 2016, compared with the prior 12-month period.
Rimini Street has opened its local office in Gangnam District, Seoul, and already supports a fast-growing base of 25 clients with South Korean operations, including large established global brands such as NCH Corporation, Transaction Network Services and EBSCO. These enterprises benefit from significant annual savings compared to software vendor maintenance fees, and enjoy ultra-responsive support with an average engineer response time of less than five minutes for urgent cases.
New Leader Brings Enterprise Software and CIO Experience
As Rimini Street South Korea’s new country manager, Sangyoul Kim will lead the sales and delivery of Rimini Street’s award-winning premium software support service. Mr. Kim is a seasoned IT industry veteran with more than 20 years of experience in software implementation, software upgrades, consulting, outsourcing, sales, and delivery, working with many of South Korea’s leading IT and industrial companies.
Mr. Kim held management positions at EDS Korea and A.T. Kearney, and most recently served as executive vice president of ISTN, where he was responsible for IT service sales and delivery. He also served previously as executive vice president of DBCS, overseeing IT service sales and delivery and as the CIO of Hanwha Group, where he was responsible for strategic IT investments and innovation initiatives for more than 15 Hanwha affiliates. During his career, Mr. Kim has provided IT consulting services to many well-known South Korean companies including Samsung, Hyundai, LG, Lotte Group and Korea Telecom. Mr. Kim served as an officer in the ROK Army, and received M.S. and Ph.D. degrees in Industrial Engineering from Seoul National University.
“Economic challenges, increased global competition, and a need for growth are forcing South Korean companies to achieve cost reduction, enable business innovation and improve efficiencies. Accordingly, CIOs are finding it increasingly hard to justify the high cost of their SAP and Oracle enterprise software maintenance and support in comparison to the value received. IT leaders in South Korea want to invest in big data, cloud, IoT and other disruptive technologies to help their organizations drive greater growth, but are struggling to find the IT budgets required to make these important, game-changing investments,” said Mr. Kim. “This is why there is such strong demand for Rimini Street independent software support in South Korea as a solution to these challenges. Rimini Street is the global leader in independent maintenance services for more than a decade, proven at over 1,450 successful clients, including over 135 Fortune 500 and Fortune Global 100 clients. We look forward to enabling South Korean businesses to benefit from Rimini Street’s premium, hyper-responsive support model that provides support for a guaranteed minimum of 15 years without any required upgrades, and that can save clients up to 90 percent in total maintenance costs.”
“For over a decade, Rimini Street has been focused on developing and delivering the most robust and innovative independent software support program available today, and we are pleased to officially launch our local operations in South Korea, led by our new country manager, Sangyoul Kim. South Korea is the third largest economy in Asia, and is already demonstrating strong demand for our support services,” said Seth Ravin, CEO, Rimini Street. “We have helped numerous SAP and Oracle licensees around the world maximize their IT investments and realize greater innovation agility, and look forward to continuing our expansion and presence in accordance with our global business plan.”
About Rimini Street, Inc.
Rimini Street is the global leader in providing independent enterprise software support services. The company has redefined enterprise support services since 2005 with an innovative, award-winning program that enables Oracle and SAP licensees to save up to 90 percent on total support costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,450 global, Fortune 500, midmarket, and public sector organizations from a broad range of industries have selected Rimini Street as their trusted, independent support provider. To learn more, please visit http://www.riministreet.com.
This press release may contain forward-looking statements. The words “believe,” “may,” “will,” “plan,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties, and are based on various assumptions. If the risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Rimini Street assumes no obligation to update any forward-looking statements or information, which speak only as of the date of this press release.
Rimini Street and the Rimini Street logo are trademarks of Rimini Street, Inc. All other company and product names may be trademarks of their respective owners. Copyright © 2016. All rights reserved.
Rimini Street, Inc.
Michelle McGlocklin, +1 925-523-8414
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom